Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.80 |
| ▸ | ATR | Q13535 | 13/20 | 0.60 |
| ▸ | PRKDC | P78527 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.51 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.51 |
| ▸ | MET | P08581 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4052591 | 0.89 | EGFR (0.64) | EGFRATRFGFR1FGFR2FGFR3 | |
| SCHEMBL4040666 | 0.89 | EGFR (1.00) | EGFRATRPRKDCATMFGFR1 | |
| SCHEMBL4042032 | 0.87 | EGFR (0.62) | EGFRATRFGFR1FGFR2FGFR3 | |
| SCHEMBL4045729 | 0.86 | EGFR (0.60) | EGFRATRFGFR1FGFR2FGFR3 | |
| SCHEMBL4043236 | 0.85 | EGFR (0.79) | EGFRATRPRKDCATMMET | |
| SCHEMBL4043542 | 0.85 | EGFR (0.59) | EGFRATRFGFR1FGFR2FGFR3 | |
| SCHEMBL3952099 | 0.83 | EGFR (0.59) | EGFRATRFGFR1FGFR2FGFR3 | |
| SCHEMBL992230 | 0.83 | MET (0.67) | EGFRMETKCNH2 | |
| SCHEMBL4044744 | 0.83 | EGFR (0.56) | EGFRFGFR1FGFR2FGFR3MET | |
| SCHEMBL3950078 | 0.83 | EGFR (0.72) | EGFRATRFGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009024825-A1 | 2-PYRAZINYLBENZIMIDAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |